Search results
Results from the WOW.Com Content Network
The AstraZeneca R&D facility in Mölndal near Gothenburg, Sweden The new AstraZeneca Corporate HQ under construction in Cambridge, United Kingdom AstraZeneca develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in the oncology , cardiovascular , gastrointestinal , infection , neuroscience , respiratory ...
The consolidation of AstraZeneca's global R&D footprint will have an impact on sites in the United States. ... oncology and infectious disease. AstraZeneca operates in over 100 countries and its ...
It is being developed by AstraZeneca. [2] It is being investigated as a treatment for pancreatic cancer with a phase 1 trial (University of Michigan researchers are as of 2019 planning a phase 2 study. [3]), and ovarian cancer, in combination with another anti-cancer drug, gemcitabine, as a phase 2 trial. [4] [5] [6]
AstraZeneca's global research and development facility, The Discovery Centre, is located on the campus [7] and is home to over 2,000 employees working in medicines discovery and development, in both small molecules and biologics.
Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.
Baselga was born on 3 July 1959, in Barcelona in Spain. [5] He received his M.D. and Ph.D. degrees from the Autonomous University of Barcelona in 1982. [6] He completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York, and subsequently stayed on as a faculty member of its Breast Medicine Service.
The patent holder is MedImmune, a subsidiary of AstraZeneca. [7] MedImmune discontinued development of CAT-3888 in 2008 and continues to develop CAT-8015. [8] Early Phase I results find that CAT-8015 exhibits a greater affinity for CD22 than CAT-3888. [9]
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.